People
Badrul Chowdhury, director of the U.S. Food and Drug Administration (FDA)’s Center for Drug Evaluation and Research (CDER)’s Division of Pulmonary, Allergy and Rheumatology Products, has left the agency to take a position as senior vice president of research development at AstraZeneca and MedImmune.
Sangamo Therapeutics recently filed a notice with the U.S. Securities and Exchange Commission (SEC) describing a data security breach. The incident underlines what appears to be a trend of cyber thieves attacking the biopharma industry.
GlaxoSmithKline Chief Executive Officer Emma Walmsley continues to hone her leadership team with a hire who will focus on potential research and development deals.
Less than one week after licensing three non-alcoholic steatohepatitis (NASH) programs from Eli Lilly, startup company Terns Pharmaceuticals has strengthened its leadership team with the appointment of two scientific advisors.
Biotech investor Vivek Ramaswamy has launched another company. This time his company, dubbed Genevant, will focus on the development of RNA-based therapies and is the combined product of Roivant Sciences and Arbutus Biopharma Corporation.
The people at Eloxx Pharmaceuticals share a common goal — to bring safe and effective therapies to children and adults suffering from rare genetic diseases as quickly as possible.
Storm-tossed Theranos continues to get battered from the continued fallout from the myriad of self-inflicted problems it has faced over the past few years. Now the company has reportedly laid off an additional 100 employees as it strives to avoid shutting down from bankruptcy.
Shares of Ironwood Pharma have settled a bit after the company announced Monday that activist investor Alex Denner of Sarissa Capital was vying for a seat on the company board of directors.
Pfizer, based in New York City, and Allogene Therapeutics, based in South San Francisco, entered into an asset contribution deal, as well as a $300 million Series A round.
Scott Smith, Celgene’s chief operating officer, abruptly resigned Monday. His decision to leave appears to be prompted by a restructuring of the company’s executive team.
PRESS RELEASES